Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...

Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...

Chronic Kidney Disease (CKD) has become a growing challenge. A top doctor shared some of its main causes, ways to prevent it from becoming serious, and how to manage it through diet and early medical ...

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...

A 37-year-old father of two developed fatigue and rib pain. Within weeks, he was diagnosed with advanced colon cancer. He's now in a promising clinical trial.

Your kidneys do this automatically by passing your blood through millions of filtering units called nephrons, which have two main parts: the glomerulus and the tubule. The glomerulus is made up of ...

The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Doctors warn that subtle symptoms like fatigue, foamy urine, swelling or lower back pain may signal early kidney problems ...

March is National Kidney Month. Learn how to protect your kidney health, recognize symptoms, and reduce your risk of disease.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

India is witnessing a worrying rise in chronic kidney disease cases, especially in young people.

Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone ...